HC Wainwright Reiterates "Buy" Rating for Pyxis Oncology (NASDAQ:PYXS)

Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $5.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 313.22% from the stock's previous close. HC Wainwright also issued estimates for Pyxis Oncology's Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $0.24 EPS.

A number of other equities research analysts have also issued reports on PYXS. William Blair lowered shares of Pyxis Oncology from an "outperform" rating to a "market perform" rating in a report on Thursday, November 21st. Royal Bank of Canada reaffirmed an "outperform" rating and set a $8.00 target price (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $9.20.

Pyxis Oncology Stock Up 8.0 %

Shares of NASDAQ:PYXS traded up $0.09 during trading on Wednesday, hitting $1.21. 912,320 shares of the stock traded hands, compared to its average volume of 744,638. The company has a market cap of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11. The company has a fifty day moving average price of $1.33 and a two-hundred day moving average price of $2.35. Pyxis Oncology has a 52-week low of $0.99 and a 52-week high of $6.18.

Remove Ads

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.01. The company had revenue of $16.15 million during the quarter. On average, equities research analysts predict that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PYXS. ProShare Advisors LLC acquired a new position in shares of Pyxis Oncology during the 4th quarter valued at about $26,000. Caption Management LLC purchased a new stake in Pyxis Oncology during the fourth quarter worth about $35,000. Ameriprise Financial Inc. purchased a new stake in Pyxis Oncology during the fourth quarter worth about $35,000. Commonwealth Equity Services LLC increased its stake in Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after purchasing an additional 10,000 shares during the period. Finally, Graham Capital Management L.P. purchased a new stake in Pyxis Oncology during the fourth quarter worth about $47,000. Institutional investors and hedge funds own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.